Claims for Patent: 10,888,570

Summary for Patent: 10,888,570

Title:	Spironolactone aqueous compositions
Abstract:	Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Inventor(s):	Pipho; Anthony (Winterville, NC), DeHart; Michael Paul (Winterville, NC)
Assignee:	CMP DEVELOPMENT LLC (Farmville, NC)
Application Number:	16/878,092
Patent Claims:	1. A ready-to-use liquid formulation, comprising: (a) about 0.20% w/v to about 1.0% w/v of spironolactone; (b) from about 0.18% w/v to about 0.36% w/v of a xanthan gum; (c) a pharmaceutically acceptable excipient; and (d) a sufficient amount of a water vehicle; wherein the formulation exhibits a content uniformity of about 100% labeled content after shaking the formulation for about 10 seconds. 2. The ready-to-use liquid formulation of claim 1, which comprises from about 0.3% w/v to about 0.8% w/v of spironolactone. 3. The ready-to-use liquid formulation of claim 2, which comprises from about 0.20% w/v to about 0.32% w/v of the xanthan gum. 4. A dosage container comprising the ready-to-use liquid formulation of claim 1. 5. The ready-to-use liquid formulation of claim 1, which comprises from about 0.4% w/v to about 0.6% w/v of spironolactone. 6. The ready-to-use liquid formulation of claim 5, which comprises from about 0.20% w/v to about 0.32% w/v of the xanthan gum. 7. A dosage container comprising the ready-to-use liquid formulation of claim 1. 8. The container of claim 7 comprised of an enclosed bottle, wherein the bottle comprises a polyethylene terephthalate and an amber colorant. 9. The bottle of claim 8 having a volume of said bottle of 4 oz. or 16 oz. 10. The ready-to-use liquid formulation of claim 1, which comprises about 0.5% w/v of spironolactone. 11. The ready-to-use liquid formulation of claim 10, which comprises about 0.25% of the xanthan gum. 12. The ready-to-use liquid formulation of claim 11, wherein the pharmaceutically acceptable excipient is selected from the group consisting of an anti-foaming agent, a preservative, a dispersing agent, a sweetening agent, a flavoring agent, a buffer to maintain the pH of the formulation from 4.5 to 5.5, and a combination thereof. 13. The ready-to-use liquid formulation of claim 12, wherein the pharmaceutically acceptable excipient is selected from the group consisting of from 0.2% w/v to 0.6% w/v of an anti-foaming agent, from 0.125% w/v to 0.250% w/v of a preservative, from 1.8% w/v to 2.4% w/v of a dispersing agent, from 0.04% w/v to 0.6% w/v of a sweetening agent, from 0.1% w/v to 0.5% w/v of a flavoring agent, a sufficient amount of a buffer to maintain the pH of the formulation from 4.5 to 5.5, and a combination thereof. 14. The ready-to-use liquid formulation of claim 13, wherein the buffer is selected from the group consisting of an acetate buffer, an aconitate buffer, a glutarate buffer, a glutamate buffer, a malate buffer, a succinate buffer, a tartrate buffer, a citrate buffer, and a phosphate buffer. 15. The ready-to-use liquid formulation of claim 14, wherein the sufficient amount of buffer ranges from about 10 mM to about 100 mM. 16. The ready-to-use liquid formulation of claim 13, wherein the buffer comprises a citrate buffer. 17. A dosage container comprising the ready-to-use liquid formulation of claim 13. 18. The container of claim 17 comprised of an enclosed bottle, wherein the bottle comprises a polyethylene terephthalate and an amber colorant. 19. The bottle of claim 18 having a volume of said bottle of 4 oz. or 16 oz. 20. The ready-to-use liquid formulation of claim 13, wherein a uniform content amount of spironolactone of about 100% l.c. is achieved within about 5 seconds of shaking.